Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

Key Points

• M2BPGi serves as a strong indicator of recurrence in hepatocellular carcinoma after hepatectomy, with potential clinical use.
• The biomarker shows minimal heterogeneity across studies, enhancing its reliability in clinical settings.
• Utilizing preoperative serum levels of M2BPGi allows for easy measurement, simplifying monitoring procedures.
• A robust association with recurrence risk emphasizes the importance of accurate biomarker detection in managing HCC.